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Abstract: PBRM1, a component of the chromatin remodeller SWI/SNF, is often deleted or mutated
in human cancers, most prominently in renal cancers. Core components of the SWI/SNF complex
have been shown to be important for the cellular response to hypoxia. Here, we investigated how
PBRM1 controls HIF-1α activity. We found that PBRM1 is required for HIF-1α transcriptional
activity and protein levels. Mechanistically, PBRM1 is important for HIF-1α mRNA translation, as
absence of PBRM1 results in reduced actively translating HIF-1α mRNA. Interestingly, we found
that PBRM1, but not BRG1, interacts with the m6A reader protein YTHDF2. HIF-1α mRNA is
m6A-modified, bound by PBRM1 and YTHDF2. PBRM1 is necessary for YTHDF2 binding to HIF-1α
mRNA and reduction of YTHDF2 results in reduced HIF-1α protein expression in cells. Our results
identify a SWI/SNF-independent function for PBRM1, interacting with HIF-1α mRNA and the
epitranscriptome machinery. Furthermore, our results suggest that the epitranscriptome-associated
proteins play a role in the control of hypoxia signalling pathways.
Keywords: PBRM1; HIF-1; SWI/SNF; YTHDF2; m6A; hypoxia
1. Introduction
The cellular response to decreased oxygen tension (hypoxia) is characterised by
changes in the gene expression program primarily mediated by the hypoxia-inducible
factor (HIF) family of transcription factors. HIF transcription factors are heterodimers
composed of an oxygen-labile HIF-α subunit and a constitutively expressed HIF-1β sub-
unit. In well-oxygenated cells, HIF-α subunits are targeted for proteasomal degradation by
sequential proline hydroxylation and polyubiquitination mediated by proline hydroxylases
(PHDs) and the Von Hippel–Lindau (VHL) E3 ubiquitin ligase, respectively [1]. In hypoxic
cells, PHD enzymes are inhibited, leading to the stabilisation and accumulation of HIF-α
isoforms. This results in active transcription of HIF target genes [2].
In order to facilitate the extensive changes in gene expression necessary for the cel-
lular response to hypoxic stress, changes to the chromatin structure must take place for
transcription factors such as HIF to access the promoter regions of its target genes. Chro-
matin exists in a spectrum of closed and open conformations determined by the density of
nucleosomes, with active transcription requiring an open conformation of chromatin so
that protein complexes can bind to the underlying DNA [3]. One mechanism of regulating
chromatin structure is through the action of ATP-dependent remodelling complexes, which
can result in either increased or decreased gene transcription [3]. There are four families of
ATP-dependent remodelling complexes, imitation switch (ISWI), chromodomain helicase
DNA-binding (CHD), INO80 and switch/sucrose non-fermentable (SWI/SNF). Each sub-
family is specialised to preferentially achieve particular chromatin outcomes: assembly,
access or editing, and has been shown to contribute to gene expression changes in response
to hypoxic stress [3,4].
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The levels and activity of SWI/SNF chromatin remodelling complexes are important
for controlling gene expression changes in hypoxia [5]. SWI/SNF complexes are a family
of large multisubunit complexes containing at least 8–12 subunits including an ATPase
module, either BRG1 or BRM1, which exert a sliding force to displace nucleosomes to
allow the binding of the transcriptional machinery to the promoters of target genes [6].
The function of SWI/SNF complexes is defined by the composition of subunits within
each subcomplex with PBAF containing PBRM1, ARID2 and PFH10, while BAF complexes
contain the ARID1A/B protein [6].
We have previously shown that the SWI/SNF components BAF155, BAF57 and BRG1
are required for HIF-1α mRNA expression, and their depletion impairs the HIF-dependent
hypoxic response [7]. Indeed, not only is chromatin remodelling necessary for HIF-1α
mRNA expression, but both BRG1 and BRM are required for full activation of HIF-1 and
HIF-2 target gene expression in Hep3B, RCC4T and SW13 cells [8]. More recent work has
shown overexpression of the SWI/SNF subunit, protein polybromo-1 (PBRM1), increases
the levels of both HIF-1α and HIF-2α target genes (PHD2, GLUT3, BNIP3) [9], suggesting
PBRM1 could regulate HIF-1α in a similar way to other SWI/SNF complex members.
Interestingly, PBRM1 along with the HIF-1α and HIF-2α E3 ligase, VHL, is the most
frequently mutated gene in clear cell renal cell carcinoma (ccRCC) [10].
PBRM1 is a large (193 kDa) multidomain protein containing six bromodomains which
bind to acetylated histones, BAH domains which are protein-binding domains [11] and an
HMG domain which has been shown to bind to the DNA minor groove [12]. Although
PBRM1 is a core component of the PBAF complex, numerous studies have demonstrated
nucleosome remodelling-independent functions of PBRM1 including localisation with
kinetochores during mitosis [12], sister chromatid cohesion [13], DNA double-strand break
repair [14] and interferon signalling [15,16]. Therefore, how PBRM1 levels and activity can
alter the HIF-dependent hypoxic response is not yet clear.
Here, we investigated the involvement of PBRM1 in regulating HIF activity. We found
that PBRM1 is required for full HIF activity and HIF-1α protein levels. However, this
regulation occurs through promoting efficient translation of HIF-1α mRNA rather than
through direct effects on HIF-1α gene transcription. This activity is supported by PBRM1’s
ability to bind selectively to HIF-1α mRNA as well as the RNA-binding protein YTHDF2,
which is also required for normal levels of HIF-1α protein in specific cellular backgrounds.
This reveals a function for PBRM1 distinct from chromatin regulation and the rest of the
SWI/SNF complex and suggests that the epitranscriptome and its machinery are important
for the cellular response to hypoxia.
2. Materials and Methods
2.1. Cell Culture and Treatment
Cell lines were obtained from the European Collection of Cell Cultures. The cell lines
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco/ThermoFisher,
Paisley, UK) supplemented with 2 mM L-glutamine, 10% (v/v) foetal bovine serum (FBS)
(Gibco/ThermoFisher, Paisley, UK), 50 units/mL penicillin (Lonza, Slough, UK) and
50 µg/mL streptomycin (Lonza, Slough, UK). HRE-luciferase reporter cell lines were main-
tained in these conditions supplemented with 0.5 µg/mL puromycin. All the cell lines
were routinely tested for mycoplasma contamination using a MycoAlert kit from Lonza.
Hypoxia treatments were performed in an InVivo 300 or InVivo2 hypoxia workstation
(Baker Ruskinn, Bridgend, Wales) at 1% O2, 5% CO2 and 37 ◦C. The cells were treated with
MG132 (Calbiochem/Millipore, Feltham, UK) at the final concentration of 20 µM, cyclohex-
imide (Millipore, Feltham, UK) at the final concentration of 0.1 mg/mL, actinomycin D at
the final concentration of 5 µg/mL and FG-4592 (Selleckchem/Stratech, Cambridge, UK)
at the final concentration of 50 µM.
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2.2. Transfection of siRNA and DNA
Transfections in HeLa, U2OS, H1299 and A549 were performed using INTERFERin
(Polyplus, Illkirch, France) following the manufacturer’s instructions. The HEK293 cells
were transfected with 0.12 M CaCl2 and HEPES buffered saline (0.156 M NaCl, 0.375 M
Na2HPO4, 10 mM HEPES were mixed with water to the final volume of 400 µL and added
to the cells). The cell culture medium was changed 24 h following transfection and the
cells were harvested 48 h following transfection. GFP-PBRM1 was a kind gift of Prof.
Jessica Downs and was described in [14]. For DNA transfections, 1 ug of plasmid DNA
was transfected per well of a six-well plate. Small interfering RNA (siRNA) oligonu-
cleotides (Eurofins) were transfected at 27 nM. The siRNA oligonucleotide sequences
were as follows: control, CAGUCGCGUUUGCGACUGG; PBRM1_A GAAGAAAGCAU-
UAAGGUAU; PBRM1_B UCAGGACGUCTCAUTAGCGAA; YTHDF2 AAGGACGTTCC-
CAATAGCCAA.
2.3. Immunoblotting
The cells were lysed in the RIPA buffer (50 mM Tris-HCl (pH 8), 150 mM NaCl, 1%
(v/v) NP40, 0.25% (w/v) Na deoxycholate, 0.1% (w/v) SDS, 10 mM NaF, 2 mM Na3VO4 and
1 tablet/10 mL cOmplete, Mini, EDTA-free protease inhibitors (Roche)), centrifuged for
10 mins at 13,000 rpm at 4 ◦C, collecting the supernatant for analysis. SDS-PAGE and im-
munoblotting were performed using standard protocols. The following primary antibodies
were used for immunoblotting: HIF-1α (610958, BD Biosciences, Workingham, UK), HIF-2α
(sc-13596, Santa Cruz, Dallas, TX, USA), HIF-1β (3718, Cell Signalling, Leiden, Holland),
β-Actin (3700, Cell Signaling, Leiden, Holland/60009-1-Ig, Proteintech, Manchester, UK),
PBRM1 (ABE70, Millipore, Feltham, UK), YTHDF2 (24744-1-AP, Proteintech, Manchester,
UK/80014, Cell Signaling, Leiden, Holland), GFP (2956, Cell Signaling), BRG1 (Santa Cruz,
Dallas, TX, USA, sc-17796). Following incubation with a horseradish peroxidase-conjugated
secondary antibody (Cell Signalling Technology, Leiden, Holland), chemiluminescence
(Pierce/ThermoFisher, Paisley, UK) was detected. All the figures are representative of a
minimum of three independent experiments.
2.4. Luciferase Assay
The cells lines stably expressing the HRE-luciferase reporter were transfected and/or
treated as indicated before lysis in a passive lysis buffer. Luciferase assays were performed
according to the manufacturer’s instructions (Promega, Southampton, UK) and activity
was measured using a Lumat LB 9507 luminometer (EG&G Berthold, Bad Wildbad, Ger-
many). The results were normalised according to protein concentration and reported as a
percentage of control.
2.5. Quantitative PCR (qPCR)
RNA from the HeLa cells was extracted using a peqGOLD total RNA kit (Peqlab,
Bishop’s Waltham, UK), from the HEK293 cells—using a Direct-Zol RNA MiniPrep kit
(Zymo Research, Irvine, USA) according to the manufacturers’ protocols. RNA was reverse-
transcribed using a Quantitect Reverse Transcription kit (Qiagen, Manchester, UK). Real-
time PCR was performed using the Brilliant II SYBR Green kit (Stratagene/Agilent, Stock-
port, UK) on an Mx3005P qPCR machine (Stratagene/Agilent, Stockport, UK). Levels of
mRNA were calculated based on averaged Ct values and normalized to β-actin mRNA
levels. The following primers were used for qPCR: HIF-1α forward CATAAAGTCTG-
CAACATGGAAGGT, HIF-1α reverse ATTTGATGGGTGAGGAATGGGTT, HIF-1β for-
ward CAAGCCCCTTGAGAAGTCAG, HIF-1β reverse GAGGGGCTAGGCCACTATTC,
β-actin forward CCCAGAGCAAGAGG, β-actin reverse GTCCAGACGCAGGATG, HK2 for-
ward AGCCCTTTCTCCATCTCCTT, HK2 reverse AACCATGACCAAGTGCAGAA, PHD2
forward GAAAGCCATGGTTGCTTGTT, PHD2 reverse TGTCCTTCTGGAAAAATTCG,
PHD3 forward CTTGGCATCCCAATTCTTGT, PHD3 reverse ATCGACAGGCTGGTC-
CTCTA, GLUT1 forward TCAAAGGACTTGCCCAGTTT, GLUT1 reverse GATTGGCTC-
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CTTCTCTGTGG, VEGF forward AGCTGCGCTGATAGACATCC, VEGF reverse CTAC-
CTCCACCATGCCAAGT, BNIP3 forward GCCCACCTCGCTCGCAGACAC, BNIP3 re-
verse CAATCCGATGGCCAGCAAATGAGA.
2.6. Polysome Profiling
The HeLa cells were transfected in 10-cm plates. Translation was stimulated by
changing the media 1.5 h before lysis. Cycloheximide in the amount of 0.1 mg/mL was
added 10 mins before lysis. The cells were washed twice with 5 mL ice-cold PBS containing
0.1 mg/mL cycloheximide. The cells were collected in 300 µL PBS with cycloheximide, and
the PBS was removed by centrifugation. The cells were resuspended in 550 µL polysome
extraction buffer (15 mM Tris-HCl (pH 7.5), 15 mM MgCl2, 300 mM NaCl, 1% Triton X-100,
1 mM DTT, 0.1 mg/mL cycloheximide and RNAsein (Sigma)). Cellular debris was pelleted
by centrifugation at 17,000× g for 1 min at 4 ◦C. The supernatant in the amount of 500 µL
was added to 10 mL 10–50% sucrose gradients (with the extraction buffer without Triton
X-100). The gradients were centrifuged using an SW41 rotor at 223,000× g for 2 h at 4 ◦C.
The gradient was collected in 1 mL fractions. RNA was extracted from the solution with
an RNAeasy extraction kit (Qiagen) according to the manufacturer’s protocol. RNA was
converted to cDNA using a Quantitect Reverse Transcription kit (Qiagen) on a SureCycler
8800 (Agilent) and an Mx3005P qPCR machine. Brilliant II SYBR Green (Agilent) was used
to perform qPCR on an Mx3005P (Agilent).
2.7. Coimmunoprecipitation
The cells were lysed in the RIPA buffer and the lysate was diluted with an equal
volume of the buffer (50 mM Tris-HCl (pH 8.0), 0.5 mM DTT, 20% glycerol, 5 mM NaF,
500 mM Na3VO4 and 1 EDTA-free protease inhibitor tablet per 10 mL buffer). The cell
lysate in the amount of 500 µg per condition was incubated with 2 µg PBRM1 antibody
(Bethyl Labs. Montegomety, AL, USA, A301-591A) or 2 µg IgG control (Sigma, Gillinham,
UK) and rotated at 4 ◦C overnight. Immune complexes were captured with 20 µL protein
G Sepharose beads (Generon. Slough, UK) by incubating with rotation for 1.5 h at 4 ◦C.
The beads were washed three times with PBS, then the beads were boiled with 20 µL SDS
loading buffer.
2.8. RNA Immunoprecipitation
Either the HeLa or H1299 cells were grown in 15-cm plates, washed twice with ice-
cold PBS, harvested in ice-cold PBS and pelleted. Of these cells, 10% were used for each
condition. The cells were lysed with 100 µL RIP lysis buffer (Magna RIP, Millipore, Feltham,
UK) and snap frozen. The cells were thawed and centrifuged at 15,000× g. The supernatant
was diluted 10-fold with the Magna-RIP wash buffer. The magnetic beads were coated
with 5 µg of the appropriate antibody for 30 mins at room temperature. The beads were
incubated with the cell extract with rotation overnight at 4 ◦C. The beads were then washed
six times with the RIP wash buffer. After setting aside 10% of the beads for IP control, RNA
was eluted by treatment with proteinase K according to the manufacturer’s instructions,
then purified by phenol–chloroform extraction followed by an 80% ethanol wash. RNA
was finally dissolved in water, converted to cDNA and quantified with qPCR comparing
to 500 ng of the input.
2.9. In Vitro RNA Binding Assay
For RNA bait preparation, DNA duplexes containing T7 promoter sequence (5′-
TAATACGACTCACTATAG-3′) followed by either the HIF-1αUTR (CAGTGCTGCCTCGTCTGA)
or the luciferase mRNA control sequence (GGAGCCCCTGCTAACGACATTTACAAC-
GAG) were generated by PCR. RNA was generated with transcription by the T7 RNA
polymerase according to the manufacturer’s instructions (Thermo Fisher, Paisley, UK).
Each 20-µL reaction was spiked with 200 ng DNA template and 0.5 µM biotin-labelled
CTP. The reaction mixture was then treated with 2 units of DNase and incubated at 37 ◦C.
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The RNA was purified using an RNA purification column (PeqGOLD, Peqlab, Bishop’s
Waltham, UK). The secondary structure was ensured by heating to 90 ◦C followed by 2 min
of incubation on ice and adding 50 µL RNA structure buffer (10 mM Tris-HCl (pH 7.4),
100 mM KCl, 10 mM MgCl2, 1 mM DTT, 0.4 U/µL RNase inhibitor, Sigma, Gillinham, UK).
RNA was conjugated to beads by mixing 100 µL of each RNA with 20 µL streptavidin
agarose beads (Sigma, Gillinham, UK, S1638) and incubating with mixing for 30 min at 4 ◦C.
The beads were washed twice with 5 mM Tris-HCl (pH 7.4), 1 M NaCl. Ten-centimetre
plates of PC-3 cells per pulldown were lysed in a buffer (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.1 mM PMSF and 0.5 mM DTT, supplemented with an EDTA-free
protease inhibitor tablet (Roche, Welwyn Garden city, UK)). The cells were homogenised
on ice using 10 strokes of a Dounce homogeniser, then centrifuged at 16,100× g for 15 min
at 4 ◦C. The supernatant in the amount of 1 mg was incubated with each of the bead-
conjugated RNAs for 3 h at 4 ◦C, then washed three times with a wash buffer (25 mM
Tris-HCl (pH 7.4), 150 mM KCl, 2 mM MgCl2, 1 mM DTT, 0.5% IGEPAL, 1 mM PMSF,
0.4 U/µL RNAse inhibitor, supplemented with an EDTA-free protease inhibitor tablet
(Roche, Welwyn Garden city, UK)). The proteins present were analysed by SDS-PAGE
and immunoblotting.
2.10. Recombinant Protein Expression and In Vitro Pulldown Assay
The E. coli BL21 DE3 (Invitrogen) cells were transformed with plasmids containing
6xHis-tagged YTHDF2 (1–384, 384–579 or 1–579) and PBRM1 (BAH1 and 2 967–1287
or HMG 1394–1462 domains). The secondary cultures in the amount of 250 mL were
inoculated and grown to OD600nm 0.6, then induced with 0.5 mM IPTG and incubated with
shaking overnight at 18 ◦C. The cells were pelleted, resuspended in a lysis buffer (0.1 M
Tris, pH 8, 0.5 M NaCl, 5% glycerol, 20 mM imidazole, 1 mM β-ME, protease inhibitor
tablet), then sonicated for 60 s in 10-s pulses at 80% amplitude on ice. The lysed cells were
centrifuged at 40,000× g and the clarified lysate was mixed with 40 µL Ni-NTA affinity
resin for 4 h at 4 ◦C. The beads were washed in the lysis buffer for 15 mins, then 1 mg
of the HeLa cell lysate was added and the mixture was incubated at 4 ◦C overnight with
rotation. The beads were then washed three times with a wash buffer (50 mM Tris pH 7.4,
200 mM NaCl, 5% glycerol, 0.1% Tween-20, 1 mM DTT). The beads were boiled with an
SDS loading buffer and analysed by Western blotting.
3. Results
3.1. PBRM1 Is Required for HIF Transcriptional Activity
As previously discussed, SWI/SNF chromatin remodeller activity has been associated
with HIF-dependent and -independent responses in hypoxia [7–9]. Furthermore, several
SWI/SNF complex members are often mutated in cancer. Of note, PBRM1 is often mutated
in renal cancer, where the HIF system plays an important role in the oncogenic process [10].
To specifically examine the effects of PBRM1 in the control of HIF activity, siRNA oligonu-
cleotides were used to deplete PBRM1 in a variety of cell lines containing an HRE-luciferase
reporter prior to exposure to hypoxia. PBRM1 levels were effectively depleted by two
independent siRNAs as determined by immunoblotting (Figure 1A). PBRM1 depletion
resulted in a significant decrease in HIF activity in all the cell lines tested (Figure 1A).
We then investigated if this was also reflected at the level of endogenous HIF-dependent
targets using qPCR. We were able to detect significant decreases in the levels of HK2,
PHD2 and PHD3 mRNA in the HeLa cells (Figure 1B) but not of GLUT1 mRNA levels
(Figure 1B). In the HEK293 cells, PBRM1 depletion resulted in decreased mRNA levels of
all the HIF targets we investigated (Figure 1C). These results suggest that knockdown of
PBRM1 inhibits hypoxia-induced HIF activity in multiple cell lines.
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Figure 1. PBRM1 is required for HIF transcriptional activity. (A) The HeLa, U2OS and HEK293 HRE-luciferase reporter 
cell lines were transfected with either control (Cnt) or PBRM1 (PB1) siRNAs for 48 h prior to lysis and exposed to 1% O2 
for 24 h prior to lysis. Cell lysates were assayed for luciferase activity and Western-blotted. The graphs display the means 
Figure 1. PBRM1 is required for HIF transcriptional activity. (A) The HeLa, U2OS and HEK293 HRE-luciferase reporter
cell lines were transfected with either control (Cnt) or PBRM1 (PB1) siRNAs for 48 h prior to lysis and exposed to 1% O2
for 24 h prior to lysis. Cell lysates were assayed for luciferase activity and Western-blotted. The graphs display the means
and standard deviations (SD) of a minimum of three independent biological replicates with ANOVA significance indicated
(* p ≤ 0.05, ** p ≤ 0.01). +, signifies specific treatment. (B) The HeLa cells and (C) the HEK293 cells were transfected and
treated with hypoxia as before. Total RNA was extracted, and mRNA levels were assessed by qPCR, normalised to actin and
compared to control siRNA. The graphs depict the means and SD of a minimum of three independent biological replicates
with ANOVA significance indicated (* p ≤ 0.05, ** p ≤ 0.01. *** p ≤ 0.001).
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3.2. PBRM1 Is Required for HIF-1α Protein Expression in Normoxia and Hypoxia
HIF activity is primarily regulated by the availability of the oxygen-sensitive HIF-α
subunits. This is dependent on the degradation of HIF-α by the proteosome. To investigate if
PBRM has a role in regulating their abundance, levels of HIF-1α and HIF-2α were measured
by immunoblotting in hypoxic cells in which PBRM1 levels were depleted using siRNA.
Interestingly, depletion of PBRM1 specifically reduced the levels of hypoxia-induced HIF-
1α (Figure 2A, Supplementary Figure S1A) but did not reduce the levels of the HIF-2α
(Figure 2A, Supplementary Figure S1B) or HIF-1β subunits (Figure 2A). Conversely, PBRM1
overexpression increased the levels of hypoxia-induced HIF-1α but, again, had little effect on
other HIF subunits (Figure 2B). We next investigated if inhibiting the proteosome would alter
PBRM1-dependent reduction of HIF-1α protein levels. Analysis of PBRM1 depletion in the
HeLa and HEK293 cells showed that HIF-1α levels could not be restored by treating cells with
the proteosome inhibitor MG132 (Figure 2C). This was also the case when we co-depleted
proteosomal component RPN11 with PBRM1 (Supplementary Figure S2A). Consistent with
this observation, we were not able to detect changes in the stability of HIF-1α protein when
PBRM1 was depleted (Supplementary Figure S2B). We were able to show that overexpression
of PBRM1 led to increased levels of HIF-1α in the presence or absence of MG132 (Figure 2D).
These results were similar to the observed effects following depletion of the core SWI/SNF
subunits we had previously investigated in U2OS cells [7], suggesting a role in transcriptional
regulation via BRG1. To confirm this hypothesis, we analysed the role of PBRM1 in the
cells that have impaired BRG1, A549 and H1299 lung cancer cells [17]. Surprisingly, PBRM1
depletion in these cells resulted in similar reduction in HIF-1α levels following MG132
treatment (Figure 2E). These results indicated that PBRM1 regulation of HIF-1α occurs through
a mechanism independent of BRG1.
3.3. PBRM1 Binds Selectively to HIF-1α mRNA and Promotes Polysome Processing
Our analyses of how PBRM1 controls HIF-1α suggest a mechanism that differs from
that of SWI/SNF components BAF155, BAF57 and BRG1, regulation of HIF-1α transcrip-
tion [7]. To investigate this, we examined HIF mRNA levels in the Hela cells after PBRM1
siRNA depletion. HIF-1α, HIF-2α and HIF-1β transcript levels all increased when PBRM1
was depleted (Figure 3A). Knockdown of BRG1 led to a reduction in HIF-1α mRNA level
as expected (Figure 3B). Furthermore, PBRM1 depletion did not change HIF-1α mRNA
in the HEK293 (Figure 3C) and H1299 cells (Figure 3D). We ruled out PBRM1 depletion
decreasing HIF-1α mRNA stability (Figure S3A). Clearly, PBRM1 does not regulate HIF
activity through transcriptional regulation but has a function different from that of other
SWI/SNF complex members.
It is known that PBRM1 can bind to DNA as part of its function on the PBAF com-
plex [12], but we investigated whether it could bind to RNA as a mechanism for regulating the
expression of HIF-1α. Using an RNA immunoprecipitation (RIP) assay, we found that PBRM1
can bind to HIF-1α mRNA (Figure 3E) as well as to mRNAs of other hypoxia-responsive
HIF target genes (Supplementary Figure S4A), revealing a novel function of PBRM1. This
RNA binding capacity was confirmed with an in vitro RNA binding assay demonstrating that
PBRM1 can bind to HIF-1α mRNA via the 5′ UTR (Figure 3F). This RNA binding demonstrates
specificity as PBRM1 was unable to bind to a control mRNA sequence.
As PBRM1 depletion could decrease HIF-1α protein levels but not transcript levels,
we next investigated HIF-1α translation. Global protein synthesis, as well as translation
rates of individual mRNAs, can be measured by polysome profiling, a technique in which
free ribosomes can be separated from mRNA-bound ribosomes (polysomes) on a sucrose
gradient. Quantitative PCR analysis of polysome-associated HIF-1α mRNA revealed that
PBRM1 depletion caused a decrease in HIF-1α mRNA association with actively translating
ribosomes consistent with a decrease in HIF-1α translation efficiency (Figure 3G,H). Impor-
tantly, no change was detected in the levels of polysome-associated mRNAs for HIF-2α and
HIF-1β (Supplementary Figure S4B). These data suggest that HIF-1α mRNA translation is
sensitive to levels of PBRM1.
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Figure 2. PBRM1 is required for HIF-1α protein levels independently of proteasomal degradation. (A) The HeLa and
HEK293 cells were transfected for a total of 48 h with either control or PBRM1 (PB1) siRNAs before exposure to treatments
with 1% O2 of different duratio , +, signifies specific treatment. Whol -cell lysat s ere analysed by Western blotting to
assess HIF isoform protein levels. (B) The HeLa and HEK293 cells were transfected with 1 µg of either the GFP empty
vector or a plasmid containing GFP-PBRM1. The cells were then exposed to 1% O2 for treatments of different duration.
Whole-cell lysates were analysed by Western blotting to assess HIF isoform protein levels. (C) The HeLa and HEK293 cell
lines were transfected with control or PBRM1 siRNAs, then treated with DMSO or MG132 for 3 h before lysis. Whole-cell
lysates were analysed by Western blotting to assess HIF-1α protein levels. (D) The HEK293 cells were transfected with 1 µg
of either the GFP empty vector or increasing amounts of a plasmid containing GFP-PBRM1. The cells were then treated
with DMSO or MG132 for 3 h before lysis. Whole-cell lysates were analysed by Western blotting to assess HIF-1α protein
levels. (E) The H1299 and A549 cells were transfected with control or PBRM1 siRNAs, then treated with DMSO or MG132
for 3 h before lysis. Whole-cell lysates were analysed by Western blotting to assess HIF-1α protein levels.
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(* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). (E) The HeLa cells were transfected with either control or PBRM1 siRNAs; then,
48 h later, they were lysed and incubated with the PBRM1 antibody coupled to magnetic beads. After washing, any RNA
present was converted to cDNA and analysed by qPCR using primers for HIF-1α. The means and standard deviations are
plotted with ANOVA significance indicated (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). (F) Biotinylated control and HIF-1α RNA
bait were conjugated to beads, then incubated with 1 mg HeLa cell lysate. The beads were washed and PBRM1 protein
levels were assessed by Western blotting. +, signifies specific treatment. (G) The HeLa cells were transfected with control
or PBRM1 siRNA and lysed 48 hours later. The clarified HeLa cell lysate was added to a 10–50% sucrose gradient and
centrifuged at 223,000× g, then collected in fractions. RNA was extracted and levels of HIF-1α were determined by qPCR for
each fraction and reported relative to actin levels. The means and standard deviations are plotted with ANOVA significance
indicated (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). (H) The ratios of mRNA between polysomal (7–10) and monosomal (1–6)
fractions are shown for actin and HIF-1α transcripts with and without mRNA knockdown of PBRM1. The means and
standard deviations are plotted with ANOVA significance indicated (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001).
3.4. PBRM1 but Not BRG1 Can Bind to the m6A-Binding Protein YTHDF2
Due to our unexpected observations that PBRM1 controlled HIF-1α levels through
translational control, we interrogated the PBRM1 interactome using IP-MS (data not
shown) to identify known translational regulators and RNA binding proteins as inter-
actors of PBRM1. Among these, we found YTHDF2, which can recognise and bind to
m6A-methylated RNA [18]. We were able to validate this observation using Western blot-
ting, identifying that PBRM1 binds YTHDF2 in normoxia and reduced binding in hypoxia
(Figure 4A). Interestingly, treatment with a PHD inhibitor (FG-4592) only slightly reduced
the interaction between PBRM1 and YTHDF2 at four hours of treatment (Figure 4B). Using
bacteria-expressed recombinant YTHDF2 as bait and the total HeLa cell lysate, we were
able to detect a robust interaction with PBRM1 (Figure 4C). However, when the YTHDF2
protein was expressed in two parts, this interaction was either abolished (N-terminal part)
or significantly reduced (C-terminal part). We were also able to determine that PBRM1
can interact with YTHDF2 via its HMG domain, while expression of BAH1 and 2 domains
was insufficient to bind YTHDF2 (Figure 4D). Furthermore, treatment with RNAse A had
no effect on the binding between YTHDF2 and the HMG domain of PBRM1 (Figure 4E),
indicating that the interaction between YTHDF2 and PBRM1 is not dependent on the
presence of RNA, but is more likely mediated by protein–protein interaction. Consistent
with our data presented above, immunoprecipitation of the BRG1 complex, which also
contains PBRM1, does not bind YTHDF2, suggesting that PBRM1 has functions outside of
the canonical PBAF complex (Figure 4F).
3.5. PBRM1 Is Required for YTHDF2 Binding to HIF-1α mRNA and for HIF-1α
Protein Expression
Our data suggest that HIF-1α RNA could be m6A methylated. To investigate this
further, publicly available datasets were interrogated [19–23]. Our analysis revealed that
HIF-1α has indeed been identified both in human and mouse tissues as being m6A-
modified, and also as bound by YTHDF2 in mouse cells [20] (Supplementary Table S1).
We next determined if we could validate this observation in our cell system. Indeed, we
confirm that HIF-1α mRNA is m6A-modified and can be bound by YTHDF2 (Figure 5A). To
determine the interplay between YTHDF2 and PBRM1 in regulating HIF-1α, we depleted
PBRM1 by siRNA and assessed HIF-1α mRNA transcript bound to YTHDF2 (Figure 5B)
Our results indicated that YTHDF2 binding to HIF-1α mRNA requires the presence of
PBRM1 (Figure 5B). To investigate the functional significance of PBRM1 binding to YTHDF2,
we determined if YTHDF2 was required for HIF-1α protein expression. Depletion of
YTHDF2 decreased HIF-1α protein following MG132 treatment in both the HeLa and H1299
cell lines (Figure 5C,D), demonstrating their requirement for HIF-1α protein expression.
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Figure 4. PBRM1 but not BRG1 can bind to the m6A-binding protein YTHDF2 in cells and in vitro. (A) The HeLa cells
were exposed to 1% O2 treatments of different duration. The cell lysate in the amount of 500 µg was immunoprecipitated
with either the PBRM antibody or the IgG control. Levels of PBRM1 and YTHDF2 were determined by Western blotting.
Input represents 10% of the protein. (B) The HeLa cells were treated with 50 µM of FG-4592 for the indicated periods of
time. The cell lysate in the amount of 500 µg was immunoprecipitated with either the PBRM1 antibody or the IgG control.
Levels of PBRM1 and YTHDF2 were determined by Western blotting. Input represents 10% of the protein. Note: * indicates
a heavy chain, the rrow indica s the YTHDF2 signal. (C) Recombinant His-tagged domain of YTHDF2 or (D) PBRM1
bound to Ni-NTA beads were incubated with 1 mg of the total HeLa cell lysate overnight at 4 ◦C and then washed; protein
levels were analysed by Western blotting. Input represents 10% of the protein. (E) Recombinant His-tagged PBRM1 HMG
domains (1394–1462) bound to Ni-NTA beads were incubated with 1 mg of the total HeLa cell lysate overnight at 4 ◦C with
or without 50 µg of RNAse A and then washed; YTHDF2 levels were analysed by Western blotting. Input represents 10% of
the protein. (F) The HeLa cell lysate in the amount of 500 µg was immunoprecipitated with either the BRG1 antibody or the
IgG control. Levels of BRG1 and YTHDF2 were determined by Western blotting. Input represents 10% of the protein.
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Figure 5. HIF-1α mRNA is m6A-modified and bound by YTHDF2. (A) The HeLa cells were lysed and incubated with 
either m6A or YTHDF2 antibodies; then, bound HIF-1α mRNA was analysed by qPCR. (B) The HeLa and H1299 cells 
were then transfected with either control or PBRM1 siRNAs and incubated with the IgG control or YTHDF2 antibodies 
before analysis of HIF-1α mRNA levels. The means and standard deviations are plotted with Student’s t-test significance 
indicated (** p ≤ 0.01). (C) The HeLa or H1299 cells were transfected with control, PBRM1 or YTHDF2 siRNAs and either 
Figure 5. HIF-1α mRNA is m6A-modified and bound by YTHDF2. ( ) e e a cells were lysed and incubated with
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before analysis of HIF-1α mRNA levels. The means and standard deviations are plotted with Student’s t-test significance
indicated (** p ≤ 0.01). (C) The HeLa or H1299 cells were transfected with control, PBRM1 or YTHDF2 siRNAs and either
DMSO or MG132 for 3 h; then, the cells were lysed and protein levels were determined by Western blotting. +, signifies
specific treatment.
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Taken together, our data demonstrate a previously unknown function of PBRM1,
outside the SWI/SNF complex and in cooperation with the epitranscriptome, in the control
of HIF-1α mRNA fate.
4. Discussion
Here, we investigated the role of PBRM1, a component of the SWI/SNF complex,
in the regulation of the HIF response. We used a variety of cancer and non-cancer cell
lines in this study. Components of the SWI/SNF chromatin remodeller are frequently
mutated in cancer [24], and as such, understanding their role in conditions of hypoxia, a
stress prevalent in malignancies, is of importance. We found that PBRM1 is required for
HIF transcriptional activity through promoting HIF-1α protein synthesis. Unlike the core
members of the SWI/SNF complex [7], PBRM1 can promote efficient translation of HIF-1α
mRNA though polysome processing. This activity is supported by PBRM1’s ability to bind
selectively to HIF-1α mRNA along with the m6A RNA-binding protein YTHDF2, which is
also required for normal levels of HIF-1α protein. Our data reveal a function for PBRM1
that is separate from its involvement in the SWI/SNF complex as PBRM1 is able to control
HIF-1α protein in the absence of a functional ATPase. Furthermore, we found that HIF-1α
is modified by m6A, suggesting that RNA methylation is required for full efficiency of the
hypoxia-inducible pathway.
There is a precedent for RNA binding activity within the SWI/SNF complex with the
catalytic subunits BRG1 and BRM interacting with lncRNA and mRNA [25,26]. Some RNA
processing has been shown to occur co-transcriptionally [27] with the PPB1 subunit of
RNA polymerase II acting as a platform for recruiting machinery for 5’-end capping, splic-
ing, polyadenylation and histone methylation [28,29]. Chromatin structure can influence
the RNA fate as H3K4me3 has been shown to recruit the RNA-capping machinery [30].
SWI/SNF has been shown to affect the elongation rate of RNA Pol II, influencing alterna-
tive exon inclusion [31]. PBRM1 contains a HMG domain, which is known to bind DNA,
and in some cases preferentially bind RNA [32,33]. We found that PBRM1 is able to bind to
HIF-1α mRNA in cells and in vitro. This demonstrates a new function of PBRM1 which is
independent of its role in a catalytic SWI/SNF complex as PBRM1 depletion also affects
HIF-1α levels in H1299 cells which are deficient in BRG1 [17,34]. It would therefore be of
interest to conduct an unbiased analysis using RIP-seq, for example, to determine how
widespread this new PBRM1 function is. An unusual function of PBRM1 was very recently
reported [35]. PBRM1 was found to bind to methylated microtubules. This binding was
necessary to recruit the SWI/SNF members to the mitotic spindle and ensure genomic
stability [35] Our results similarly show that PBRM1 binds methylated sites, though in
RNA, however, this seems to be independent of the other SWI/SNF components.
In hypoxia, global translation is reduced, regulated at the stage of initiation [36],
posing a paradox with the increases in protein levels of hypoxia-inducible genes. Several
mechanisms are proposed to contribute to the selective translation of HIF-1α mRNA in
hypoxia (reviewed in [37]). Our analysis revealed that HIF-1α mRNA is m6A-modified.
This has also been seen in an unbiased genome-wide analysis of this modification [21,23].
More than 150 different posttranscriptional modifications have been identified on cellular
RNAs [38], with the most abundant being the m6A methylation within the coding region
or UTRs of the RNA, particularly in mRNAs [18]. RNA methylation is “written” by the
methyltransferase complex METTL3/14, WTAP, RBM15/15B and KIAA1429, “erased”
by the demethylases FTO and ALKBH5 and recognised or “read” by YTHDF1/2/3 [18].
RNA m6A modification regulates RNA splicing [39], processing [39], decay [40] and
translation [20,41]. N6-methyladenosine acts as a binding site for several reader proteins,
including YTHDF2. YTHDF2 binding is normally associated with increased RNA degra-
dation [42]. However, under stress conditions such as heat shock, YTHDF2 translocates
to the nucleus and protects 5′ UTR m6A, which promotes cap-independent translation of
target genes [21]. A similar mechanism may operate for HIF-1α mRNA, as we found that
YTHDF2 becomes more nuclear-located in response to hypoxia (Supplementary Figure S5).
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This suggests a role for YTHDF2 in locating to recently transcribed RNA in the nucleus
and contributing to hypoxia-selective translation in cells.
Our data suggest that PBRM1 is required for efficient HIF-1α protein translation.
However, in hypoxia, we observed a reduced interaction between PBRM1 and YTHDF2,
suggesting that, potentially, another m6A reader might come into play. Further analysis
investigating m6A levels in hypoxia and PBRM1 interaction could provide answers to
these remaining questions. However, the importance of PBRM1 is still present in hypoxia,
as reduced HIF-1α protein translation in the absence of PBRM1 is still observed under this
condition. This indicates that reductions in transcription [7,37] and translation in normoxia
impact HIF-1α protein levels in hypoxia.
Although the analysis of the epitranscriptome has not been conducted in hypoxia,
there are existing links between these two aspects. The m6A eraser proteins, FTO and
ALKBH5, are 2-oxoglutarate dioxygenases, meaning they use 2-oxoglutarate, iron and
oxygen as cofactors. Although their oxygen affinity might be too high to participate in the
hypoxia response [43], ALKBH5 has been shown to be a target of HIF-1α [44]. This suggests
that, indeed, hypoxia can influence the epitranscriptome in a cell. Furthermore, studies of
liver cancer have shown that hypoxia can increase the levels of m6A in mRNA [45]. More
recently, METTL3, one of the m6A writers, has been shown to promote hypoxia-induced
hypertension in pulmonary arteries [46]. Our data demonstrating that HIF-1α is m6A-
modified adds to the hypothesis that, indeed, the epitranscriptome is an integral part of
the cellular response to hypoxia.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cells10061425/s1, Figure S1: PBRM1 is required for hypoxia induction of HIF-1α, Figure S2:
PBRM1 does not alter HIF-1α protein stability, Figure S3: PBRM1 does not alter HIF-1α mRNA stabil-
ity, Figure S4: PBRM1 does not alter the translation of HIF-1β or HIF-2α, Figure S5: Hypoxia induces
nuclear accumulation of YTHDF2, Table S1: Analysis of public RIP/PAR-Clip data for HIF-1α.
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